Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea (PUNCH CD)
A Phase 2 Open-label Clinical Trial Demonstrating the Safety of RBX2660 Microbiota Suspension for the Treatment of Recurrent Clostridium Difficile-associated Diarrhea (CDAD): the PUNCH CD Study
Sponsor: Rebiotix Inc.
Listed as NCT01925417, this PHASE2 trial focuses on Recurrent Clostridium Difficile Infection and remains completed. Sponsored by Rebiotix Inc., it has been updated 11 times since 2013, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Oct 2018 — Dec 2019 [monthly]
Completed PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Completed PHASE2
-
Jul 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Jul 2017 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Aug 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Rebiotix Inc.
For direct contact, visit the study record on ClinicalTrials.gov .